{"slug":"vip-frozen-shoulder","title":"VIP for Frozen Shoulder: Evidence Review","body":"## What's breaking down if you have Frozen shoulder\n\nFrozen shoulder, also called adhesive capsulitis, involves progressive inflammation and thickening of the shoulder joint capsule. This leads to adhesions, reduced synovial fluid, and fibrosis that restricts motion. The capsule contracts, creating stiffness and pain that typically lasts months to years. Breakdown occurs in inflammatory and fibrotic layers, where immune overactivity and tissue remodeling outpace normal repair. Autonomic and immune signaling can amplify local inflammation without direct mechanical trauma in many idiopathic cases.\n\n## Why VIP might help you\n\n1. You are reading about **Frozen shoulder** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf your frozen shoulder involves heightened immune and autonomic responses driving capsule inflammation, VIP is studied for its ability to modulate those signals. VIP acts on VPAC receptors to shift cytokine balance, potentially lowering pro-inflammatory mediators while supporting tissue homeostasis. This could allow repair processes to catch up in the capsule rather than perpetual degeneration from ongoing immune activation. The framing stays on regeneration pathways, not symptom suppression.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **VIP** → immune / autonomic\n\n## What the evidence actually shows\n\nNo human clinical trials exist for VIP in frozen shoulder. Searches returned zero randomized or controlled human studies linking VIP administration to adhesive capsulitis outcomes (tier: speculative for this exact condition).\n\nPreclinical work shows VIP effects in other inflammatory joint models. In one mouse study of collagen-induced arthritis, VIP treatment delayed onset, lowered incidence, and reduced severity of joint disease while downregulating inflammatory and autoimmune components (tier: preclinical). Another rodent model demonstrated VIP prevents experimental arthritis via suppression of MMP-2 and inflammatory cascades (tier: preclinical). A review of the VIP axis in rheumatic diseases notes VIP inhibits TNF-α, IL-6, and other mediators while boosting IL-10 in synovial cells from osteoarthritis and rheumatoid arthritis patients (tier: mechanistic with some human cell data).\n\nOne PRP-focused paper on adhesive capsulitis briefly references VIP in the context of anti-inflammatory mechanisms but provides no direct testing or data on VIP itself (tier: anecdotal mention).\n\nHuman evidence inventory: 0 trials. Animal/in vitro: several arthritis models. Anecdotal: none located for VIP specifically.\n\n## What scientists say\n\nResearchers describe VIP as an endogenous neuropeptide with immunomodulatory properties that restores immune homeostasis in inflammatory settings. Reviews emphasize its potential in autoimmune and rheumatic conditions through cytokine regulation, though they note translation to specific shoulder pathologies remains untested in people (tier: mechanistic).\n\n## What people say on Reddit\n\nNo relevant user reports or discussions linking VIP to frozen shoulder outcomes appear in targeted searches. General frozen shoulder communities focus on standard therapies like physical therapy or PRP.\n\n## What people say on X\n\nNo posts connecting VIP treatment to frozen shoulder recovery or experiences were identified.\n\n## What we do not know\n\nDirect effects of VIP on shoulder capsule fibrosis, range of motion, or pain in humans are unknown. Whether VIP influences autonomic contributions to frozen shoulder or interacts with common comorbidities remains unstudied. Long-term outcomes and specificity to adhesive capsulitis versus other arthritides lack data.\n\n## Safety and limits\n\nVIP research in joint models reports no major toxicity in short-term animal work, but human safety data for this application is absent. All discussion stays within observed mechanisms and preclinical findings; no clinical application is implied.","register":"source_ledger","tags":["peptide","matrix"],"category":null,"style":{},"claims":[{"id":"c1","text":"Frozen shoulder involves inflammation, capsule thickening, adhesions, and fibrosis restricting motion.","section":"What's breaking down if you have Frozen shoulder","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes baseline degeneration layers for context."},{"id":"c2","text":"VIP modulates immune responses by inhibiting pro-inflammatory cytokines like TNF-α and IL-6 while increasing IL-10 in synovial cells.","section":"Why VIP might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Supports immune/autonomic layer targeting."},{"id":"c3","text":"In collagen-induced arthritis mouse models, VIP delayed onset and reduced severity of joint disease.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Closest analog data; not frozen shoulder specific."},{"id":"c4","text":"No human trials exist for VIP in frozen shoulder or adhesive capsulitis.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap."}],"sources":[{"id":"s1","type":"medical","url":"https://orthoinfo.aaos.org/en/diseases--conditions/frozen-shoulder","title":"Frozen Shoulder - Adhesive Capsulitis","quote":"In frozen shoulder, the shoulder capsule thickens and becomes stiff and tight. Thick bands of tissue — called adhesions — develop.","summary":"AAOS overview of frozen shoulder pathology.","claim_ids":["c1"]},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6982157/","title":"A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases","quote":"VIP modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells.","summary":"Review of VIP immunomodulation in rheumatic diseases.","claim_ids":["c2"]},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6092975/","title":"The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide","quote":"This study demonstrated that VIP treatment dramatically suppresses clinical joint disease in murine collagen-induced arthritis.","summary":"Preclinical arthritis model results.","claim_ids":["c3"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}